Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Chembio Diagnostics logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Key Stats

Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

Quest Diagnostics Inc DGX
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
See More Headlines

CEMI Stock Analysis - Frequently Asked Questions

Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The business earned $12.06 million during the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/04/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-23,290,000.00
Pretax Margin
-46.96%

Debt

Sales & Book Value

Annual Sales
$48.34 million
Book Value
$0.48 per share

Miscellaneous

Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:CEMI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners